Prelude Therapeutics (PRLD) Preferred Stock Liabilities (2019 - 2020)

Prelude Therapeutics has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $59.8 million for Q2 2020.

• Preferred Stock Liabilities for Q2 2020 came in at $59.8 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2020 was $59.8 million (changed N/A YoY), and the FY2019 annual result was $66.4 million, changed N/A from the prior year.
• Preferred Stock Liabilities came in at $59.8 million for Q2 2020 at Prelude Therapeutics, up from $36.6 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $66.4 million in Q4 2019 to a low of $29.8 million in Q3 2019.